Vinod Vathipadiekal
Overview
Explore the profile of Vinod Vathipadiekal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sethi G, Pathak H, Zhang H, Zhou Y, Einarson M, Vathipadiekal V, et al.
PLoS One
. 2012 Oct;
7(10):e47086.
PMID: 23056589
Targeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of...
12.
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin Z, Li T, et al.
Mol Cancer Res
. 2012 Sep;
10(11):1462-72.
PMID: 22964433
Epithelial ovarian cancer (EOC) ranks first as the cause of death for gynecological cancers in the United States. SUZ12 is a component of the polycomb repressive complex 2 (PRC2) and...
13.
Verma A, White M, Vathipadiekal V, Tripathi S, Mbianda J, Ieong M, et al.
J Immunol
. 2012 Aug;
189(5):2478-87.
PMID: 22851708
The collectins have been shown to have a role in host defense against influenza A virus (IAV) and other significant viral pathogens (e.g., HIV). The ficolins are a related group...
14.
Vathipadiekal V, Saxena D, C Mok S, Hauschka P, Ozbun L, Birrer M
PLoS One
. 2012 Jan;
7(1):e29079.
PMID: 22272227
Identification of gene expression profiles of cancer stem cells may have significant implications in the understanding of tumor biology and for the design of novel treatments targeted toward these cells....
15.
Li H, Bitler B, Vathipadiekal V, Maradeo M, Slifker M, Creasy C, et al.
Cancer Prev Res (Phila)
. 2011 Dec;
5(3):484-91.
PMID: 22144423
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy in the United States. EZH2 silences gene expression through trimethylating lysine 27 on histone H3 (H3K27Me3). EZH2 is often overexpressed...
16.
McCann C, Growdon W, Kulkarni-Datar K, Curley M, Friel A, Proctor J, et al.
PLoS One
. 2011 Dec;
6(11):e28077.
PMID: 22140510
Background: Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, basal cell, small cell lung, pancreatic, prostate and ovarian. This investigation was...
17.
Stany M, Vathipadiekal V, Ozbun L, Stone R, C Mok S, Xue H, et al.
PLoS One
. 2011 Jul;
6(7):e21121.
PMID: 21754983
Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these...
18.
C Mok S, Bonome T, Vathipadiekal V, Bell A, Johnson M, Wong K, et al.
Cancer Cell
. 2009 Dec;
16(6):521-32.
PMID: 19962670
Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify...
19.
Vathipadiekal V, Umasankar P, Patole M, Rao M
Peptides
. 2009 Oct;
31(1):16-21.
PMID: 19818820
The aspartic protease inhibitor (ATBI) purified from a Bacillus sp. is a potent inhibitor of several proteases including recombinant HIV-1 protease, pepsin, and fungal aspartic protease. In this study, we...
20.
Vathipadiekal V, Verma A, Rao M
Biol Chem
. 2007 Jan;
388(1):61-5.
PMID: 17214550
This is the first report describing the enhancement of xylanase activity by the neutral amino acid glycine. Xylanase activity is increased seven-fold at alkaline pH in the presence of glycine...